ArticleScientific reports2025
Morin combined with meropenem is a potent inhibitor of NDM-1 against NDM-1-producing E. coli.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Some β-lactam antibiotics are hydrolyzed by the enzyme New Delhi metallo-β-lactamase 1 (NDM-1), increasing antibiotic resistance and posing a significant threat to public health. Thus, there is an urgent need to develop and use potent inhibitors of NDM-1 and other β-lactamases. This study evaluated the effects of the flavonoid morin (3,5,7,2',4'-pentahydroxyflavone) on the antimicrobial activity of β-lactams and the interaction between morin and NDM-1. New NDM-1 inhibitors were identified by the structure-based virtual screening of natural product libraries. The interaction between morin and NDM-1 was evaluated by molecular docking. The impact of morin on β-lactam activity was assessed in vitro using checkerboard tests, kill-time kinetics, and broth microdilution. The effect of morin on the anti-inflammatory activity of meropenem (MEM) in BALB/c mice infected with NDM-1-producing Escherichia coli was evaluated by ELISA. The impact of morin and MEM on mouse tissue damage was assessed by hematoxylin and eosin staining. The interaction mechanisms between morin and NDM-1 were examined using molecular dynamics simulations. Molecular docking showed that morin inhibited NDM-1. Morin alone did not inhibit the growth of NDM-1-producing E. coli. However, morin combined with β-lactams suppressed bacterial growth and reduced their MIC 4- to 32-fold. Morin combined with MEM decreased tissue damag Morin enhanced antibacterial activity of β-lactams against NDM-1-producing E. coli when combined with MEM. These findings establish the foundation for using morin in developing potent inhibitors for NDM-1 and other β-lactamases to reduce antibiotic resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.